Literature DB >> 18411288

Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.

Fumiki Momoi1, Tomomi Hashizume, Tomoko Kurita-Ochiai, Yoshikazu Yuki, Hiroshi Kiyono, Masafumi Yamamoto.   

Abstract

In this study, we demonstrated that the 40-kDa outer membrane protein of Porphyromonas gingivalis (40-kDa OMP) nasally administered with a nontoxic chimeric adjuvant that combines the A subunit of mutant cholera toxin E112K with the pentameric B subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli (mCTA/LTB) elicited a long-term protective immune response. Immunization with the 40-kDa OMP and mCTA/LTB induced high levels of 40-kDa-OMP-specific immunoglobulin G (IgG) and IgA antibodies (Abs) in sera and elicited a significant IgA anti-40-kDa OMP Ab response in saliva. These Ab responses were maintained for at least 1 year after the immunization. Although using adjuvant mCTA/LTB gave Ab responses in the saliva comparable to those obtained using native cholera toxin (nCT) as the adjuvant, the levels of total IgE and 40-kDa-OMP-specific IgE Abs as well as interleukin-4 levels induced by the immunization with mCTA/LTB were lower than those induced by the immunization with nCT. Importantly, IgG Abs generated by nasal immunization with the 40-kDa OMP plus mCTA/LTB inhibited the coaggregation and hemagglutinin activities of P. gingivalis. Furthermore, the mice given nasal 40-kDa OMP plus mCTA/LTB showed a significant reduction of alveolar bone loss caused by oral infection with P. gingivalis even 1 year after the immunization compared to the loss in unimmunized mice. Because mCTA/LTB is nontoxic, nasally administered 40-kDa OMP together with mCTA/LTB should be an effective and safe mucosal vaccine against P. gingivalis infection in humans and may be an important tool for the prevention of chronic periodontitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18411288      PMCID: PMC2423079          DOI: 10.1128/IAI.01502-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

1.  Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.

Authors:  F W van Ginkel; R J Jackson; Y Yuki; J R McGhee
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Bactericidal activity of a monoclonal antibody against a recombinant 40-kDa outer membrane protein of Porphyromonas gingivalis.

Authors:  M Katoh; S Saito; H Takiguchi; Y Abiko
Journal:  J Periodontol       Date:  2000-03       Impact factor: 6.993

3.  Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.

Authors:  Y Hagiwara; T Iwasaki; H Asanuma; Y Sato; T Sata; C Aizawa; T Kurata; S Tamura
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

4.  Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice.

Authors:  Evanthia Lalla; Ira B Lamster; Marion A Hofmann; Loredana Bucciarelli; Adrienne P Jerud; Sid Tucker; Yan Lu; Panos N Papapanou; Ann Marie Schmidt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-19       Impact factor: 8.311

5.  Oral osteoporosis: is there an association between periodontitis and osteoporosis?

Authors:  Michael S Reddy
Journal:  Compend Contin Educ Dent       Date:  2002-10

6.  A 35-kDa co-aggregation factor is a hemin binding protein in Porphyromonas gingivalis.

Authors:  Yasuko Shibata; Koichi Hiratsuka; Mitsuo Hayakawa; Teruaki Shiroza; Hisashi Takiguchi; Yasuko Nagatsuka; Yoshimitsu Abiko
Journal:  Biochem Biophys Res Commun       Date:  2003-01-10       Impact factor: 3.575

Review 7.  Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.

Authors:  M Yamamoto; J R McGhee; Y Hagiwara; S Otake; H Kiyono
Journal:  Scand J Immunol       Date:  2001-03       Impact factor: 3.487

8.  A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies.

Authors:  Mi-Na Kweon; Masafumi Yamamoto; Fumiko Watanabe; Shinichi Tamura; Frederik W Van Ginkel; Akira Miyauchi; Hiroaki Takagi; Yoshifumi Takeda; Takashi Hamabata; Kohtaro Fujihashi; Jerry R McGhee; Hiroshi Kiyono
Journal:  J Infect Dis       Date:  2002-10-03       Impact factor: 5.226

9.  Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses.

Authors:  M Yamamoto; H Kiyono; M N Kweon; S Yamamoto; K Fujihashi; H Kurazono; K Imaoka; H Bluethmann; I Takahashi; Y Takeda; M Azuma; J R McGhee
Journal:  J Infect Dis       Date:  2000-06-30       Impact factor: 5.226

10.  Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.

Authors:  Prosper N Boyaka; Mari Ohmura; Kohtaro Fujihashi; Toshiya Koga; Masafumi Yamamoto; Mi-Na Kweon; Yoshifumi Takeda; Raymond J Jackson; Hiroshi Kiyono; Yoshikazu Yuki; Jerry R McGhee
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

View more
  9 in total

Review 1.  Periodontitis: a polymicrobial disruption of host homeostasis.

Authors:  Richard P Darveau
Journal:  Nat Rev Microbiol       Date:  2010-07       Impact factor: 60.633

2.  Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.

Authors:  Chenlu Liu; Tomomi Hashizume; Tomoko Kurita-Ochiai; Kohtaro Fujihashi; Masafumi Yamamoto
Journal:  Mol Oral Microbiol       Date:  2010-06       Impact factor: 3.563

3.  Vaccination targeting surface FomA of Fusobacterium nucleatum against bacterial co-aggregation: Implication for treatment of periodontal infection and halitosis.

Authors:  Pei-Feng Liu; Wenyuan Shi; Wenhong Zhu; Jeffery W Smith; Shie-Liang Hsieh; Richard L Gallo; Chun-Ming Huang
Journal:  Vaccine       Date:  2010-02-26       Impact factor: 3.641

4.  Mucosal immunization with a flagellin-adjuvanted Hgp44 vaccine enhances protective immune responses in a murine Porphyromonas gingivalis infection model.

Authors:  Sao Puth; Seol Hee Hong; Mi Jin Park; Hye Hwa Lee; Youn Suhk Lee; Kwangjoon Jeong; In-Chol Kang; Jeong Tae Koh; Byounggon Moon; Sang Chul Park; Joon Haeng Rhee; Shee Eun Lee
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

5.  Induction of IL-10-producing CD4+ T-cells in chronic periodontitis.

Authors:  R Kobayashi; T Kono; B A Bolerjack; Y Fukuyama; R S Gilbert; K Fujihashi; J Ruby; K Kataoka; M Wada; M Yamamoto; K Fujihashi
Journal:  J Dent Res       Date:  2011-02-18       Impact factor: 6.116

6.  Fusobacterium nucleatum envelope protein FomA is immunogenic and binds to the salivary statherin-derived peptide.

Authors:  Hidetaka Nakagaki; Shinichi Sekine; Yutaka Terao; Masahiro Toe; Muneo Tanaka; Hiro-O Ito; Shigetada Kawabata; Satoshi Shizukuishi; Kohtaro Fujihashi; Kosuke Kataoka
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

7.  Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease.

Authors:  R Kobayashi; T Kobayashi; F Sakai; T Hosoya; M Yamamoto; T Kurita-Ochiai
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

Review 8.  Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities.

Authors:  Victor Vaernewyck; Boaz Arzi; Niek N Sanders; Eric Cox; Bert Devriendt
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

9.  In situ visualization of plasma cells producing antibodies reactive to Porphyromonas gingivalis in periodontitis: the application of the enzyme-labeled antigen method.

Authors:  Y Mizutani; S Tsuge; H Takeda; Y Hasegawa; K Shiogama; T Onouchi; K Inada; T Sawasaki; Y Tsutsumi
Journal:  Mol Oral Microbiol       Date:  2014-05-10       Impact factor: 3.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.